What actually happens in week one, month three, and beyond — on Ozempic, Wegovy, Mounjaro, and Zepbound. A realistic timeline of what to expect, and how to manage it.
Almost everyone starting a GLP-1 medication wants to know two things: how much will I lose, and what will I feel? The first question gets all the headlines. The second is what actually determines whether you stick with treatment.
This is a practical timeline of the side effects most people experience on semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). The pattern is similar across all four drugs because they work through the same biological pathways. Individual response varies — some people sail through with almost nothing, others struggle for weeks. Knowing what's normal helps you tell the difference between an adjustment period and a problem worth calling your doctor about.
Side effects are most common in the first 4-8 weeks and after every dose increase. They are predominantly gastrointestinal — nausea, constipation, fatigue, reflux. The vast majority are mild to moderate and improve with time. Slow titration, hydration, and dietary changes solve most problems. Severe or persistent symptoms warrant a call to your prescriber.
Both semaglutide and tirzepatide begin at very low introductory doses (0.25 mg semaglutide weekly, 2.5 mg tirzepatide weekly). At these doses, the drug is barely doing its job — the goal is purely to let your body acclimate.
For most people, the worst of the early nausea fades during the second week. Appetite reduction becomes more pronounced. You may notice 2-4 pounds of weight loss, though some of this is reduced water and food volume rather than fat.
If you started at the lowest dose, your provider will typically increase it around week four. Be ready: the dose increase often brings a temporary return of mild nausea or fatigue for a few days as your body adjusts again.
This is when most people hit their stride. Nausea has usually faded to the point of being manageable or absent. Weight loss accelerates — typically 5-10% of body weight by the end of month two for many people, though individual variation is large.
While nausea gets most of the attention, constipation is the most persistent GLP-1 side effect for many people. It's a direct consequence of slowed gastric motility. People often suffer in silence because it feels less urgent to mention.
Weight loss often slows around months 4-6. This is normal metabolic adaptation, not failure. Many people are also at their target dose by now (or close to it), and the body has fully adjusted.
Side effects at this stage are usually minimal. If you're still experiencing significant GI symptoms, that's worth a conversation with your prescriber — sometimes a slightly lower maintenance dose works better long-term than pushing to maximum.
A 2026 analysis of self-reported symptoms from over 25,000 GLP-1 users found that among people reporting any side effect:
| Symptom | Semaglutide users | Tirzepatide users |
|---|---|---|
| Nausea | 39.4% | 28.6% |
| Vomiting | 18.0% | 11.1% |
| Fatigue | 16.1% | 14.7% |
| Constipation | 14.9% | 12.9% |
| Diarrhea | 12.4% | 12.5% |
Tirzepatide users tended to report somewhat lower rates of nausea and vomiting, consistent with what's been observed in head-to-head clinical trials.
By this point, most people have reached their target dose and most side effects have stabilized into a manageable baseline. Weight loss continues but slows. Some people reach maximum loss by month 12; others continue gradual loss through month 18.
This is also when long-term considerations come into focus.
Any significant weight loss — from medication, dieting, or surgery — includes some loss of lean mass alongside fat loss. Estimates from clinical trials suggest 25-40% of weight lost on GLP-1 drugs may come from lean tissue if no countermeasures are taken.
Two interventions reduce this dramatically:
Some people notice increased hair shedding 3-4 months after starting a GLP-1 drug. This is typically telogen effluvium — a temporary phenomenon caused by rapid weight loss, not by the medication itself. It usually resolves over 3-6 months as your body adapts. Adequate protein and iron intake help.
The categories below are uncommon but real, and worth knowing about so you can recognize warning signs.
Rare but documented. Symptoms include severe, persistent abdominal pain that radiates to the back, often with vomiting. Stop the medication and contact your doctor or seek emergency care immediately.
Rapid weight loss of any kind raises gallstone risk. Symptoms include severe upper-right abdominal pain, especially after fatty meals, sometimes with nausea or fever.
All four drugs carry a boxed warning for medullary thyroid carcinoma based on rodent studies. Human data has not confirmed the rodent finding, but these drugs should not be used by anyone with personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia type 2 (MEN 2).
Because GLP-1 drugs slow gastric emptying, food may remain in the stomach longer than expected. This is a newer concern in surgical settings and creates a risk of aspiration during anesthesia. Always tell any surgeon, anesthesiologist, or dentist performing sedation that you are taking a GLP-1 medication. Current guidance often recommends holding the medication for one to two doses before procedures.
Severe vomiting or diarrhea from GI side effects can lead to dehydration and acute kidney injury. Most cases are preventable with adequate hydration and dose adjustment if symptoms are severe.
The FDA has flagged adverse event reports tied to compounded semaglutide and tirzepatide, including cases involving incorrect doses, mis-titration, and counterfeit products. With compounded drugs increasingly restricted as both medications are now off official shortage status, the risk of obtaining an unverified product has grown.
If you are using a compounded version: verify the compounding pharmacy is state-licensed, confirm the vial concentration before each dose, and never adjust your titration schedule on your own. Counterfeit products with fake labels are a documented and growing problem.
The first month is the hardest. The second and third months get progressively easier. By month four, most people are in a stable rhythm with side effects that are manageable or absent. The medications work — but how they feel along the way depends heavily on titration pace, hydration, what you eat, and how much you move.
If you find yourself unable to eat, severely fatigued, or otherwise miserable for more than two to three weeks, that is not a normal adjustment period. Talk to your prescriber. A slightly lower dose or a slower titration schedule often resolves things, and a small percentage of people do better switching between semaglutide and tirzepatide.
Reviewed by Ben Bird. Updated April 2026